Dispersion device

Abstract

To provide a volatilization device capable of suppressing leakage of a chemical agent from an enclosure.SOLUTION: A volatilization device 1 is capable of accommodating a chemical agent container 4 including a container body 41 containing a chemical agent with an aperture closed with a volatilization membrane 442 in an enclosure 2. The enclosure 2 includes a positioning part 5 for positioning the chemical agent container 4 in the enclosure 2. In a service condition, a gap exists between a part of the volatilization membrane 442 lower than the liquid level of the chemical agent and the enclosure 2 along the whole area.SELECTED DRAWING: Figure 7

Description

[Technical Field]

[0001] The present disclosure relates to a vaporizer. [Background technology]

[0002] Patent Document 1 discloses a conventional volatilization device (a volatile composition dispenser in Patent Document 1). The volatile composition dispenser described in Patent Document 1 contains a cartridge in a housing.

[0003] The cartridge includes a container and a membrane that closes the opening of the container. The volatile composition contained in the container flows out of the container, wets the membrane, and evaporates from the membrane, thereby being dispersed into a space in which the volatile composition dispenser is placed. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Special Publication No. 2019-513494 Summary of the Invention [Problem to be solved by the invention]

[0005] In this type of dispenser, the cartridge inside the housing is positioned relative to the housing.

[0006] Generally, a positioning structure may be employed in which a protrusion protruding from the inner surface of the housing presses against the membrane of the cartridge.

[0007] However, when a portion of the film that has been wetted with the volatile composition comes into contact with the protrusion, the volatile composition may flow down the protrusion and leak out of the housing.

[0008] The present disclosure aims to provide a volatilization device that can prevent leakage of medicine from the housing. [Means for solving the problem]

[0009] The volatilization device of the present disclosure is a volatilization device capable of housing a drug container in a housing, the drug container having an opening surface of the container body containing the drug closed with a volatilization film. The housing has a positioning part that positions the drug container within the housing. In use, there is a gap over the entire surface between the volatilization film and the housing, the portion of the volatilization film that is below the liquid level of the drug.

[0010] In addition, in the volatilization device of the present disclosure, it is preferable that the positioning portion holds the container body relative to the housing.

[0011] In addition, in the volatilization device of the present disclosure, it is preferable that there is a gap between the entire surface of the volatilization film and the housing.

[0012] Furthermore, in the evaporation device of the present disclosure, the housing preferably comprises a frame having an opening on one side and a cover that closes the opening, the cover preferably having a pair of walls spaced apart from each other with at least a portion of the container body disposed between them, and each of the pair of walls preferably including a locking portion that engages with a locking portion formed on the container body.

[0013] In addition, in the volatilization device of the present disclosure, it is preferable that the volatilization membrane faces diagonally downward. [Effects of the Invention]

[0014] The volatilization device of the present disclosure has the advantage of being able to prevent leakage of the drug from the housing. [Brief explanation of the drawings]

[0015] [Figure 1] FIG. 1 is a perspective view of the volatilization device according to the embodiment, seen from the front side. [Figure 2] FIG. 2 is an exploded perspective view of the volatilization device according to the embodiment. [Figure 3] FIG. 3 is a perspective view of the volatilization device according to the embodiment, seen from the rear side. [Figure 4] Fig. 4(A) is an exploded perspective view of a frame and a movable body of the volatilization device according to the embodiment, and Fig. 4(B) is an assembled perspective view of Fig. 4(A). [Figure 5] FIG. 5 is a perspective view of the cover of the volatilization device according to the embodiment, seen from the rear side. [Figure 6] FIG. 6 is a cross-sectional view taken along line BB in FIG. [Figure 7] FIG. 7 is a cross-sectional view taken along line CC in FIG. [Figure 8] Fig. 8(A) is a cross-sectional view taken along line AA in Fig. 4(B) with a drug container added, and Fig. 8(B) is a cross-sectional view of Fig. 8(A) in a state where the movable part has moved to the second position. [Figure 9] FIG. 9 is a perspective view of a chemical container of the volatilization device according to the embodiment. [Figure 10] FIG. 10 is an exploded perspective view of the drug container according to the embodiment. [Figure 11] FIG. 11 is a cross-sectional view of a drug container according to an embodiment. [Figure 12] 12(A) to 12(C) are cross-sectional views illustrating the movement when a hole is made in the rupture membrane of the drug container according to the embodiment. DETAILED DESCRIPTION OF THE INVENTION

[0016] <Embodiment> (1) Overall The volatilization device 1 according to this embodiment is a device that volatilizes a chemical agent from a chemical agent container 4 housed therein and diffuses the chemical agent in the space in which the volatilization device 1 is installed. As shown in FIG. 1, the volatilization device 1 according to this embodiment is used by being placed on a mounting surface 1G parallel to a horizontal plane. However, there are no particular limitations on the installation manner of the volatilization device 1 according to the present disclosure. The volatilization device 1 according to the present disclosure may be installed, for example, by hanging it from a ceiling or the like, hooking it onto a handle, attaching it to a glass or mirrored surface with a suction cup, or inserting it into the louvers of a fan. In this disclosure, the "in use" state refers to the state in which the volatilization device 1 is installed in the space in which the chemical agent is to be diffused. An example of the in use state is when the volatilization device 1 is placed on the mounting surface 1G (with the lower surfaces of the legs 22 in contact with the mounting surface 1G).

[0017] As shown in Fig. 2, the volatilization device 1 includes a housing 2 having a frame 23 and a cover 29, and a movable body 3 movably attached to the housing 2. The movable body 3 and the drug container 4 are housed in the housing 2. As shown in Fig. 3, the movable body 3 has an operating unit 31. The operating unit 31 protrudes from the housing 2 and is exposed from the housing 2.

[0018] 2, the drug container 4 is configured such that the opening surface of the container body 41 containing the drug is closed by a volatilization film 442. In the drug container 4 according to this embodiment, the volatilization film 442 and the rupture film 441 are laminated, and the opening surface of the container body 41 is closed by the volatilization film 442 and the rupture film 441.

[0019] As movable body 3 moves relative to housing 2, movable body 3 ruptures rupture film 441. This causes drug container 4 to be opened, and the drug permeates volatilization film 442, causing the drug to volatilize into the space.

[0020] The chemical agent is a volatile liquid chemical agent. There are no particular limitations on the chemical agent, and examples thereof include fragrances, deodorants, insect repellents, and mixtures thereof. The chemical agent also contains additives depending on the purpose. Examples of additives include fragrances, deodorant components, insect repellent components, and coloring agents.

[0021] (2) Housing The housing 2 forms the outer shell of the volatilization device 1. As shown in FIG. 3, the housing 2 includes a main body 21 and legs 22. The front and back surfaces of the main body 21 are inclined relative to the horizontal plane. Here, when the main body 21 is viewed in a direction perpendicular to the front surface of the main body 21 (this is referred to as the "front view" of the main body 21), the direction parallel to the left-right direction is defined as the "width direction," and the direction perpendicular to the width direction is defined as the "length direction." Furthermore, the direction perpendicular to the width direction and the length direction (i.e., the direction perpendicular to the front surface of the main body 21) is defined as the "thickness direction." In the following description, the length direction of the main body 21 will be simply referred to as the "length direction." The width direction of the housing 2 will be simply referred to as the "width direction." The thickness direction of the housing 2 will be simply referred to as the "thickness direction."

[0022] The main body 21 has a flat box shape and is formed into a generally rectangular shape when viewed from the front. "Flat" here means a shape in which the thickness dimension is shorter than the width and length dimensions. The main body 21 is hollow. The length direction is inclined with respect to the lower surfaces of the legs 22 (sometimes referred to as the bottom of the housing 2) that rest on the placement surface 1G. The angle between the length direction and the lower surfaces of the legs 22 (the angle when viewed from the side) is, for example, 45° or more and less than 90°.

[0023] Housing 2 includes legs 22, a frame 23 that forms the back and side surfaces of main body 21, and a cover 29 that forms the front of main body 21, as well as a positioning portion (see FIG. 5, etc.) that positions drug container 4 within housing 2. There are no particular limitations on the material of housing 2, and examples include synthetic resin, metal, pulp, carbon, and ceramic.

[0024] (2.1) Frame The frame 23 is a part that forms the framework of the housing 2. As shown in Fig. 4, the frame 23 is formed in the shape of a container having an opening on the front surface in the thickness direction. The frame 23 includes a back plate portion 24 and side plate portions 28.

[0025] The back plate 24 constitutes the back surface of the main body 21. The upper portion of the back plate 24 is inclined relative to the horizontal plane, and the main surface of the upper portion of the back plate 24 faces in the thickness direction. The lower portion of the back plate 24 constitutes part of the leg portion 22. As shown in FIG. 4(A), the back plate 24 includes a plurality of ventilation holes 25 and an attachment portion 26.

[0026] Vent 25 is an opening through which the drug vaporized from drug container 4 passes. Vent 25 penetrates back plate 24. Multiple vents 25 are formed in parts other than the central part of back plate 24 (i.e., mounting part 26). The shape of each vent 25 is formed into a rectangular, triangular, trapezoidal, or the like depending on the location, but is not limited thereto and can also be formed into, for example, a circular, elliptical, pentagonal, hexagonal, mesh, or the like.

[0027] The mounting portion 26 is a portion for mounting the movable body 3. The mounting portion 26 is configured as a portion that forms a range in the central portion in the width direction and the central portion in the length direction of the back plate portion 24. As shown in FIG. 4(A), the mounting portion 26 includes an operation portion opening 261, a pair of holding portions 262, and a plurality of guide portions 263.

[0028] The operation unit opening 261 is an opening through which the operation unit 31 of the movable body 3 passes. The operation unit opening 261 is formed in a substantially rectangular shape. The operation unit 31 passes through the operation unit opening 261 from the inside to the outside of the housing 2 and is exposed from the housing 2. Within the operation unit opening 261, the operation unit 31 can move along the thickness direction.

[0029] The holding portion 262 is a portion that holds a part of the elastic portion 33 of the movable body 3 on the mounting portion 26. As described above, the movable body 3 can move along the thickness direction, but the elastic portion 33 is held by the holding portion 262, so that the range of movement of the movable body 3 is restricted to a certain range.

[0030] The pair of holding portions 262 are spaced apart in the length direction. In the volatilization device 1 according to this embodiment, the pair of holding portions 262 are formed at positions corresponding to both ends in the longitudinal direction (length direction) of the movable body 3. However, the pair of holding portions 262 may also be spaced apart in the width direction, in which case they should be formed at positions corresponding to both ends in the short side direction of the movable body 3.

[0031] In this embodiment, each holding portion 262 is configured by a hook-shaped claw that holds a part of the elastic portion 33 so as not to move in the thickness direction. However, the holding portion 262 is not limited to a claw, and may be configured by, for example, welding, pinning, screwing, or a bearing with a C-shaped cross section.

[0032] The guide portions 263 engage with both ends of the movable body 3 in the width direction, and move the movable body 3 parallel to the thickness direction. Examples of the guide portions 263 include ridges or rails extending in the thickness direction. For example, grooves are formed in the movable body 3. The ridges or the like fit into the grooves, and the guide portions 263 can move the movable body 3 parallel to the thickness direction.

[0033] The side plate portion 28 is a portion that protrudes in the thickness direction from the outer periphery of the back plate portion 24. The protruding tip of the side plate portion 28 forms the opening surface of the frame 23. The side plate portion 28 forms the side peripheral surface of the housing 2. In the volatilization device 1 according to this embodiment, the side plate portion 28 does not have an air vent 25 formed therein, but an air vent 25 may be formed therein.

[0034] (2.2) Cover Cover 29 is a member that closes the opening on the front side of frame 23. As shown in FIG. 2 , cover 29 closes the opening side of frame 23 with movable body 3 and drug container 4 housed within frame 23. Cover 29 has a remaining amount display window 291 that allows the remaining amount of drug in drug container 4 to be visually confirmed. Remaining amount display window 291 is composed of a through hole 294 that is formed in cover body 292 and extends in the length direction, and a transparent plate 293 that covers through hole 294. Through hole 294 is formed at a position corresponding to drug container 4 housed inside housing 2.

[0035] (2.3) Positioning part Positioning unit 5 is a part that positions drug container 4 within housing 2. Positioning unit 5 according to this embodiment positions drug container 4 so that volatilization film 442 intersects with the horizontal plane. More specifically, positioning unit 5 according to this embodiment positions drug container 4 so that volatilization film 442 faces diagonally downward.

[0036] 5, the positioning portion 5 protrudes inward in the thickness direction from the inner surface of the cover 29. When the positioning portion 5 is viewed along the thickness direction, the positioning portion 5 is formed in a substantially rectangular frame shape.

[0037] The positioning portion 5 includes a pair of first walls 511 spaced apart in the width direction and a pair of second walls 512 spaced apart in the length direction. Each first wall 511 extends in the length direction. Each second wall 512 extends in the width direction. Each first wall 511 connects ends of the pair of second walls 512 in the width direction. A corner portion 513 formed by the first wall 511 and the second wall 512 is formed in an arc shape.

[0038] Between the pair of first walls 511, there is positioned an agent accommodating section 421 (sometimes referred to as a "first section") which is a part of the agent container 4. The agent accommodating section 421 of the container body 41 is fitted between the pair of first walls 511, whereby the container body 41 is held by the cover 29.

[0039] A locking portion 55 is formed on each of the opposing surfaces of the pair of first walls. As shown in Fig. 6, the pair of locking portions 55 engage with locked portions 46 formed on the container body 41, thereby restricting movement of the container body 41 in the thickness direction away from the cover 29. The positioning portion 5 uses the locking portions 55 to keep the container body 41 in the area surrounded by the first wall 511 and the second wall 512, thereby holding the container body 41.

[0040] In this embodiment, the locking portion 55 and the locked portion 46 are both configured as protrusions. The locking portion 55 and the locked portion 46 extend in the longitudinal direction. However, in the present disclosure, the locking portion 55 and the locked portion 46 do not have to extend in the longitudinal direction and may be configured, for example, as multiple protrusions. Furthermore, the locking portion 55 and the locked portion 46 may have a structure such as a convex portion and a concave portion, a claw and a hooked portion, or a male screw and a female screw. Furthermore, the positioning portion 5 does not have to have the locking portion 55 and may be realized, for example, by fitting, press-fitting, magnetic adhesion, adhesion, suction, etc.

[0041] As a result, the positioning unit 5 positions the drug container 4 in the length direction, width direction, and thickness direction with the volatilization film 442 facing diagonally downward. Because the positioning unit 5 holds the container body 41, as shown in FIG. 7, there may be no member supporting the volatilization film 442 at the portion of the volatilization film 442 below the liquid level of the drug. That is, in this embodiment, there is a gap (space) over the entire surface between the portion of the volatilization film 442 below the liquid level of the drug and the housing 2. In other words, the portion of the volatilization film 442 below the liquid level of the drug does not come into contact with other members.

[0042] 7, the housing 2 has a rib 27 that contacts the upper end of the volatilization membrane 442. Since the rib 27 contacts a portion of the volatilization membrane 442 that is above the liquid surface of the medicine, the medicine hardly leaks out from the volatilization membrane 442 along the rib 27.

[0043] (3) Movable body The movable body 3 is a member that is provided movably relative to the housing 2. As shown in Fig. 4(A), the movable body 3 includes an operation unit 31 that is operated by a user, a movable unit 32 that constitutes the main body of the movable body 3, and a pair of elastic units 33.

[0044] The operating unit 31 can move along the thickness direction. The operating unit 31 is configured to be movable between an initial position (a position where the movable unit 32 abuts against the back plate 24; see FIG. 8(A)) and a position where the movable unit 32 opens the drug container 4 (see FIG. 8(B)). In this embodiment, within the movement range of the operating unit 31, the initial position is defined as a "first position," and the position where the movable unit 32 opens the drug container 4 is defined as a "second position."

[0045] In this embodiment, the operating portion 31, the movable portion 32, and the elastic portion 33 are integrally molded. The material of the movable body 3 is not particularly limited, and examples thereof include synthetic resin, metal, pulp, and carbon.

[0046] The movable part 32 moves integrally with the operating part 31. The movable part 32 is formed in an oval shape having a long axis (in other words, a "longitudinal axis") parallel to the lengthwise direction. The movable part 32 has a plurality of (here, two) protruding parts 321 formed at a distance from each other in the direction along the longitudinal axis.

[0047] As shown in FIG. 8(A), when the operating unit 31 is in the first position, each of the plungers 321 is separated from the drug container 4. On the other hand, as shown in FIG. 8(B), when the operating unit 31 is moved to the second position, each of the plungers 321 makes a hole in the drug container 4 to open the drug container 4. The plurality of plungers 321 are formed at both ends of the movable unit 32 in the direction along the longitudinal axis. Each plunger 321 protrudes from the surface of the movable unit 32 on the first position side in the movement direction. Examples of the shape of each plunger 321 include a spindle shape (cone shape, pyramid shape), a needle shape, a rod shape, etc., but a cone shape is preferable.

[0048] The multiple protruding portions 321 are spaced apart in the longitudinal direction (i.e., length direction) of the movable portion 32. This allows holes to be made in the drug container 4 both above and below the center of the drug container 4, as shown in Fig. 8(B). That is, the multiple protruding portions 321 can make holes in both the portion corresponding to the gas phase and the portion corresponding to the liquid phase in the drug container 4.

[0049] As a result, the upper holes of the multiple holes can be used as air intake holes, and the lower holes can be used as holes for passing the medicine. This makes it easier for the medicine to be ejected from the medicine container 4, and maintains a stable amount of medicine volatilization. Of the protrusions 321 aligned in the longitudinal direction of the movable part 32, it is preferable to drill the lower protrusion 321 as close as possible to the opening edge of the container body 41. Note that the upper side refers to the upper side when the volatilization device 1 is placed on the mounting surface 1G. The lower side refers to the lower side when the volatilization device 1 is placed on the mounting surface 1G.

[0050] The pair of elastic portions 33 are portions that connect the movable portion 32 and the housing 2. When the movable body 3 is attached to the attachment portion 26 of the frame 23, the operation portion 31 is located at the first position, as shown in FIG. 8(A). When an external force is applied to the operation portion 31 (i.e., when the operation portion 31 is pushed into the housing 2) while the operation portion 31 is located at the first position, the elastic portions 33 are elastically deformed, as shown in FIG. 8(B). At this time, the movable portion 32 moves in conjunction with the movement of the operation portion 31 from the first position to the second position (FIG. 8(A) → FIG. 8(B)). In this state, when the external force applied to the operation portion 31 is removed, the elastic portions 33 return to their original state. At this time, the movable portion 32 returns in conjunction with the movement of the operation portion 31 from the second position to the first position (FIG. 8(B) → FIG. 8(A)).

[0051] (4) Drug containers The drug container 4 is a container that contains a drug. The drug container 4 includes a container body 41, a lid 44, and a plate member 45, as shown in FIG.

[0052] (4.1) Container body The container body 41 is a part that constitutes the main body of the drug container 4. The container body 41 is made of a hard resin. There are no particular limitations on the hard resin, and examples thereof include polyethylene terephthalate, polyethylene, polypropylene, polystyrene, polycarbonate, acrylic, polyvinyl chloride, and laminates thereof. In this embodiment, the container body 41 is made of a laminate of polyethylene terephthalate and polyethylene.

[0053] The container body 41 according to this embodiment is made of a transparent resin so that the remaining amount of medicine can be visually confirmed. The term "transparent" as used herein means that the remaining amount of medicine can be visually confirmed, and includes so-called translucency. Note that in the present disclosure, the container body 41 may also be made of an opaque material.

[0054] Container body 41 includes a storage section 42 and a flange section 43. Storage section 42 is the portion of container body 41 where the medicine is stored. Storage section 42 is formed in a container shape with an opening on one side. As shown in FIG. 10 , storage section 42 includes a medicine storage section 421 and a plate material storage section 422.

[0055] The agent containing section 421 is a section in which a agent is mainly contained. As shown in Fig. 11 , the agent containing section 421 includes a bottom wall 4211 having a generally rectangular shape in a plan view, and a first side wall 4212 rising from the outer peripheral edge of the bottom wall 4211. As shown in Fig. 10 , each of the pair of first side walls 4212 is formed with an interlocking portion 46, as described above. In this embodiment, the interlocking portion 46 is a protrusion extending in the length direction.

[0056] 11, the plate material accommodating portion 422 is a portion in which the plate member 45 is accommodated, and is formed between the agent accommodating portion 421 and the flange portion 43. The plate material accommodating portion 422 includes a support portion 4221 connected to the first side wall 4212 of the agent accommodating portion 421, and a second side wall 4222 rising from the outer peripheral edge of the support portion 4221. The end of the second side wall 4222 on the flange portion 43 side forms the opening surface of the accommodating portion 42.

[0057] The thickness dimension (internal dimension) of the agent containing section 421 is not particularly limited, but is set to, for example, 5 mm or more and 20 mm or less. The thickness dimension (internal dimension) of the plate material containing section 422 is set appropriately depending on the thickness dimension of the plate member 45, but is set to, for example, 1 mm or more and 5 mm or less.

[0058] The flange portion 43 is a portion to which the lid body 44 is joined. The flange portion 43 is provided along the entire outer periphery of the opening surface of the storage portion 42. The surface of the flange portion 43 to which the lid body 44 is joined is flat. The entire surface of the flange portion 43 to which the lid body 44 is joined is located on the same plane.

[0059] (4.2) Lid Lid 44 is joined to flange 43 so as to close the opening of container body 41. Lid 44 can be joined to flange 43 by, for example, welding, adhesive bonding, or the like. Lid 44 is flexible. Lid 44 is configured by stacking a rupture film 441 and a volatilization film 442. Lid 44 is arranged in this order from the inside to the outside of drug container 4, with rupture film 441 and volatilization film 442 positioned in that order.

[0060] The rupture film 441 is configured so that when an external force is applied to the volatilization film 442 from the outside in the thickness direction, it ruptures with a smaller amount of elongation than the volatilization film 442. The rupture film 441 is made of a liquid-impermeable material. The rupture film 441 may be, for example, a thin film in which a polyethylene layer, an aluminum layer, and a polyethylene terephthalate layer are laminated.

[0061] A specific example of the rupture film 441 is a thin film in which a first polyethylene layer, an aluminum layer, a second polyethylene layer, and a polyethylene terephthalate layer are laminated in this order from the inside to the outside. In this case, for example, the thickness of the first polyethylene layer is set to 5 μm to 30 μm, the thickness of the aluminum layer is set to 5 μm to 25 μm, the thickness of the second polyethylene layer is set to 5 μm to 25 μm, and the thickness of the polyethylene terephthalate layer is set to 5 μm to 25 μm.

[0062] The volatilization membrane 442 volatilizes the medicine while retaining the medicine that has passed through the holes (rupture holes) formed in the rupture membrane 441. The volatilization membrane 442 is disposed on the outer surface of the rupture membrane 441 (the surface opposite the container body 41 in the thickness direction). The volatilization membrane 442 is less likely to rupture than the rupture membrane 441 when an external force is applied to the volatilization membrane 442 from the outside in the thickness direction. Examples of the volatilization membrane 442 include porous films such as Teslin (trademark) and Daramic (trademark).

[0063] In the drug container 4 configured as described above, as shown in Fig. 12, when the operating unit 31 moves from the first position to the second position, the plunger 321 pushes the volatilization membrane 442. Then, the plunger 321 pushes the rupture membrane 441. At this time, the volatilization membrane 442 and the rupture membrane 441 stretch, but the rupture membrane 441 ruptures first, creating a hole in the rupture membrane 441 (Fig. 12(A) → (B)). After this, when the external force on the operating unit 31 is removed, the elastic unit 33 returns the operating unit 31 from the second position to the first position, and the movable unit 32 and the plunger 321 move away from the volatilization membrane 442.

[0064] Then, the medicine inside the medicine container 4 is released to the outside through the lower hole. The medicine penetrates the volatilization membrane 442 and volatilizes. When the medicine is released, the pressure inside the container decreases, and air is taken in through the upper hole. At this time, the lower part of the volatilization membrane 442 is mainly wet from a height approximately the same as the medicine liquid level, and the part above the medicine liquid level is not wet or is only slightly wet. For this reason, the medicine is less likely to adhere to the second protruding part of the volatilization membrane 442 that presses down on the side above the medicine liquid level.

[0065] (4.3) Plate members Plate member 45 is a member for partially preventing extension of lid body 44 when an external force is applied to lid body 44. Plate member 45 makes it easier for rupture film 441 to rupture when an external force is applied. Plate member 45 is formed in a substantially rectangular plate shape, as shown in Fig. 10. There are no particular restrictions on the material of plate member 45, and examples include polypropylene, polyethylene terephthalate, polyethylene, polystyrene, polycarbonate, acrylic, polyvinyl chloride, and laminates thereof.

[0066] A plurality of (here, two) through holes 451 are formed in the plate member 45. The plurality of through holes 451 are formed at both end portions in the longitudinal direction (length direction) of the plate member 45. The through holes 451 are formed at positions corresponding to portions to which an external force is to be applied.

[0067] (5) Effects As described above, in the volatilization device 1 according to this embodiment, the volatilization film 442 has the positioning portion 5, and there is a gap over the entire surface between the portion of the volatilization film 442 below the liquid level of the chemical and the housing 2. Therefore, other members do not come into contact with the portion of the volatilization film 442 that is easily wetted by the chemical, and therefore leakage of the chemical outside the housing 2 can be suppressed.

[0068] Furthermore, since the positioning portion 5 holds the container body 41, the drug container 4 can be stably installed regardless of the orientation of the drug container 4 without other components coming into contact with the portion of the volatilization film 442 that is easily wetted by the drug.

[0069] Furthermore, by positioning part 5 holding container body 41, a gap can be formed between the entire surface of volatilization film 442 and housing 2. This makes it possible to prevent the medicine from leaking out of housing 2, even if the part of volatilization film 442 above the liquid level of the medicine becomes wet to the same extent as the part below the liquid level of the medicine.

[0070] Furthermore, since positioning portion 5 has a pair of walls 511 having locking portions 55, even if housing 2 is subjected to an impact, for example, it is possible to ensure that drug container 4 is held.

[0071] Furthermore, the positioning unit 5 positions the volatilization film 442 in a state facing diagonally downward, so that the area of ​​the volatilization film 442 that is wetted by the chemical can be widened. Therefore, the amount of volatilization from the volatilization film 442 is stabilized.

[0072] <Modification> The above embodiment is merely one of various embodiments of the present disclosure. The embodiment can be modified in various ways depending on the design, etc., as long as the object of the present disclosure can be achieved. Modifications of the embodiment are listed below. The modifications described below can be applied in appropriate combinations.

[0073] In the volatilization device 1 according to the above embodiment, the storage section 42 of the container body 41 is held by the positioning section 5, but for example, a clamping section may be provided that clamps the upper end of the volatilization film 442 and the flange section 43 in the thickness direction. That is, the drug container 4 may be held in the housing 2 by clamping the volatilization film 442 and the flange section 43 in the thickness direction, as long as they are above the liquid surface of the drug.

[0074] In the above embodiment, the locking portion 55 is formed on the first wall 511, but in the present disclosure, the locking portion 55 may be formed on both the first wall 511 and the second wall 512, or may be formed only on the second wall 512. In this case, the locked portion 46 is also formed corresponding to the locking portion 55.

[0075] In the volatilization device 1 according to the above embodiment, the movable body 3 is configured as a separate member from the housing 2, but the housing 2 and the movable body 3 may be formed as a single unit. Also, although the movable body 3 is provided, in the present disclosure, the volatilization device 1 does not need to have the function of the movable body 3, and the movable body 3 may be omitted. In the volatilization device 1 according to the present disclosure, a pre-opened drug container 4 may be placed in the housing 2.

[0076] In the above embodiment, the housing 2 is provided with the rib 27 that contacts the portion of the volatilization film 442 above the liquid surface of the medicine, but this rib 27 may be omitted.

[0077] In the above embodiment, the housing 2 is inclined relative to the placement surface 1G. However, in the present disclosure, the length direction of the housing 2 may extend perpendicular to the placement surface 1G. In this case, the volatilization film 442 may be parallel to a vertical plane or a horizontal plane in use. For example, the volatilization device 1 may be attached to the back side of a trash can lid with a suction cup or the like so that the volatilization film 442 is parallel to a horizontal plane.

[0078] Although the operation unit 31 according to the above embodiment is configured to be movable along the thickness direction, in the present disclosure, the movement direction of the operation unit 31 is not limited to the thickness direction, and the operation unit 31 may be configured to be movable along, for example, the length direction or the width direction. In this case, the operation unit 31 may protrude from the side peripheral surface of the housing 2, for example. In conjunction with the movement of the operation unit 31, the movable part 32 may move in a direction intersecting the pushing direction. Furthermore, the operation unit 31 may be operated not only by pushing, but also by sliding, rotating, pulling, etc.

[0079] In the above embodiment, the lengthwise dimension of the main body 21 is longer than the widthwise dimension, but in the present disclosure, the lengthwise dimension and the widthwise dimension may be the same, or the widthwise dimension may be longer than the lengthwise dimension. Note that in the above embodiment, the embodiment is described based on the "thickness direction," "width direction," and "lengthwise direction" of the housing 2, but the "thickness direction," "width direction," and "lengthwise direction" of the housing 2 can also be rephrased as the "first direction," "second direction," and "third direction," respectively.

[0080] In the volatilization device 1 according to the above embodiment, the chemical container 4 may be a cartridge-type chemical container in which only the chemical container can be replaced with a new chemical container 4. The "rupture membrane 441" and the "volatilization membrane 442" can also be referred to as the "first membrane" and the "second membrane", respectively.

[0081] In this specification, expressions accompanied by "approximately", such as "approximately parallel" or "approximately perpendicular", may be used. For example, "approximately parallel" means that the state is substantially "parallel", and includes not only a strictly "parallel" state but also an error of a few degrees. The same applies to other expressions accompanied by "approximately".

[0082] Furthermore, in this specification, expressions such as "end" and "edge" are used that are distinguished by the presence or absence of "... part." For example, "edge" means the end of an object, while "edge" means a region having a certain range that includes the "edge." Any point within a certain range that includes the edge is considered to be an "end." The same applies to other expressions that include "... part." [Explanation of symbols]

[0083] 1 Volatilization device 2. Case 23 frames 29 Cover 4. Medicine containers 41 Container body 442 Volatile film 46 Locked part 5 Positioning part 511 First wall (wall) 55 Locking part

Claims

1. A volatilization device capable of accommodating a drug container in a housing, the opening of which is closed with a volatilization membrane, The housing includes a positioning portion that positions the drug container in the housing so that the volatilization film faces obliquely downward, the positioning portion holds the container body relative to the housing, The housing includes: a frame having an opening on one side; a cover that closes the opening; Equipped with the positioning portion includes a pair of walls provided on the cover and spaced apart from each other, the pair of walls having at least a portion of the container body disposed therebetween; Each of the pair of walls includes a locking portion that engages with a locked portion formed on the container body, In use, there is a gap over the entire surface between the portion of the volatilization film below the liquid level of the drug and the housing. Volatilization device.

2. There is a gap between the entire surface of the volatilization film and the housing. The volatilization device according to claim 1.

Images